Advertisement

Topics

Latest "Altus Capital Partners, Inc." News Stories

12:18 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Altus Capital Partners, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Altus Capital Partners, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Altus Capital Partners, Inc. for you to read. Along with our medical data and news we also list Altus Capital Partners, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Altus Capital Partners, Inc. Companies for you to search.

Showing "Altus Capital Partners" News Articles 1–25 of 7,000+

Tuesday 19th February 2019

Partners HealthCare names interim CEO


uLab Systems Partners with Drs. Tom Pitts & Duncan Brown to Bring Smile Arc to Aligners

uLab Systems, the creator of the cutting-edge aligner planning software, is happy to announce a partnership with Drs. Tom Pitts & Duncan Brown. Dr. Pitts and Dr. Brown are known for their revolutionary approach to orthodontic aesthetics. In fact, Dr. Pitts created the ‘Smile Treatment Design,’ an orthodontic protocol that focuses on smile arc, vertical ...

$PTX Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management. Files for chapter 11 https://globenewswire.com/news-release/2019/02/19/1734397/0/en/Pernix-Therapeutics-Holdings-Inc-Enters-into-Asset-Purchase-Agreemen

$PTX Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management. Files for chapter 11 https://globenewswire.com/news-release/2019/02/19/1734397/0/en/Pernix-Therapeutics-Holdings-Inc-Enters-into-Asset-Purchase-Agreement-with-Certain-Funds-Managed-by-Highbridge-Capital-Management.html …


VetStem Biopharma Launches Human Stem Cell Company in San Diego

VetStem Biopharma has spun out Personalized Stem Cells, Inc. and licensed it with human autologous stem cell authority to begin human clinical trials using adipose stem cell technology pioneered and patented by VetStem. POWAY, Calif. (PRWEB) February 19, 2019 VetStem Biopharma has long been a leader in veterinary stem cell therapy with clinical, regulatory and manufacturing experience. In Octobe...

Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex Genprex, Inc. (NASDAQ: GN

Nativis Announces Additional Publication of Further Study in Patients with Recurrent Glioblastoma (rGBM)

Second Study Yields Additional Data Suggesting the Nativis Voyager® is Safe for Treatment of rGBM and the Potential Breadth of Technology Platform SEATTLE (PRWEB) February 19, 2019 Nativis, Inc., (http://nativis.com) a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of a second study (NAT-105...

Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome

DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance 19.02.2019 / 11:31 The issuer is solely responsible for the content of this announcement. Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome - First age-specific products for weight control by addressing the gastrointestinal microbiome - ADL Bionat...

Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference

Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018 financial results and present at the 8th Annual Leerink Partners Health Care Conference. Details of both event...

NHI Announces Increase in First Quarter 2019 Dividend

National Health Investors, Inc. (NYSE:NHI) announced today that it will increase its quarterly dividend by 5% to $1.05 per common share. Dividends are payable on May 10, 2019 to shareholders of record as of March 29, 2019. About NHI Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust ...

Covera Health Announces Series A Financing of $8.5 Million to Drive Continued Growth

Covera Health, the country’s leading provider of analytics-based programs to reduce medical misdiagnoses and improve quality of care, announced today that it has closed $8.5 million in Series A funding. The financing was led by Equity Group Investments (EGI), the private investment firm led by Sam Zell. “EGI, with their flexible capital base a...

Knight signs Latin American strategic funding deal with Moksha8

Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight The post Knight signs Latin American strategic funding deal with Moksha8 appeared first on Pharmaceutical Business review.

Knight Therapeutics signs Latin American funding deal with Moksha8

Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight The post Knight Therapeutics signs Latin American funding deal with Moksha8 appeared first on Pharmaceutical Business review.

Hardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked

Hardman & Co Research 19-Feb-2019 / 07:15 GMT/BST Hardman & Co: Transformed and de-risked Yourgene Health (YGEN) is an international molecular diagnostics group that uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests (NIPT). Its flagship IONA test uses complex statistical analyses to determine the likelihood that a fetus is carrying a gene...

Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany

                                                                                       Interim report for Enzymatica AB (publ)                                                                                   ...

Brain imaging indicates potential success of drug therapy in depressive patients

Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indicate the potential success of drug therapy in depressive patients.

Monday 18th February 2019

AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference

WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted Myles, chief financial officer and Julie Krop, MD, chief medical officer will participate in a fireside chat at 10:00 a.m. EST. A live audio webcast will be accessible through the Investors section o...

Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference

WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8th Annual Global Healthcare Conference on Friday, March 1, 2019. Information on the presentation is as follows: Event: Leerink Partners 8th Annual Global Healthcare Conference

Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced its participation at the SVB Leerink Partners Global Healthcare Conference.  The conference will be held from February 27- March 1 in New York. Corey Fishman, Chief Executive...

Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management

Transaction that includes the sale of substantially all of Pernix’s assets to be valued at $75.6 million             Pernix voluntarily files for Chapter 11 protection Pernix intends to continue to operate with no disruption to the availability of Pernix products and patient support services MORRISTOWN, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc...

CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference

TÜBINGEN, Germany and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 8th Annual Leerink Partners Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 1:50 p.m. ET. A live bro...

XFRA CAPITAL ADJUSTMENT INFORMATION - 19.02.2019 - 2

FOLGENDE WERTPAPIERE WERDEN AM 19.02.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 19.02.2019. INSTR EXCH ISIN INSTRUMENT NAME TSO XFRA TRETRBZ00016 T...

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

Developing Sample to Insight solutions to accelerate research on growing public health threat QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (Euronext: CURE), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing g...

10 Major Themes Driving The Future of Blockchain in Healthcare

Partners in Digital Health, communications company publishing the peer review journals Blockchain in Healthcare Today (BHTY) has announced their first annual BHTY Top 10 Blockchain Predictions for Healthcare 2019.  With over 20,000 downloads, 18 citations, and readership in over 65 countries worldwide, Blockchain Healthcare Today (BHTY) is the preeminent open-access international peer-revi...

CNS-focused Arvelle spins off from Axovant with planned $100mm initial round

Axovant Sciences Ltd. spun off its small-molecule platform assets into a new company, Arvelle Therapeutics GMBH, which receiv...

Teva reconnecting to Israel's startup ecosystem

After abandoning Israeli partners in the past decade, sources say that under Kare Schultz, Teva is again showing interest in Israeli drug development and digital healthcare startups.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks